These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36475152)

  • 1. Assessing Neurocognition (P300) and Correlating Them to Depression Rating Scales in Patients With Major Depressive Disorder.
    Wakode S; Hulke S; Wakode NS; Pathak T; Shrivastava R; Thakare A; Malhotra V
    Cureus; 2022 Nov; 14(11):e31084. PubMed ID: 36475152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative change in P300 indices following antidepressant treatment in patients with major depressive disorder.
    Wakode SL; Hulke SM; Sutar R; Thakare AE
    Ind Psychiatry J; 2022; 31(2):243-247. PubMed ID: 36419696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translating the HAM-D into the MADRS and vice versa with equipercentile linking.
    Leucht S; Fennema H; Engel RR; Kaspers-Janssen M; Szegedi A
    J Affect Disord; 2018 Jan; 226():326-331. PubMed ID: 29031182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An analysis of correlations among four outcome scales employed in clinical trials of patients with major depressive disorder.
    Jiang Q; Ahmed S
    Ann Gen Psychiatry; 2009 Jan; 8():4. PubMed ID: 19166588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and reliability of the HAM-D/MADRS interview: an integrated depression symptom rating scale.
    Iannuzzo RW; Jaeger J; Goldberg JF; Kafantaris V; Sublette ME
    Psychiatry Res; 2006 Nov; 145(1):21-37. PubMed ID: 17049379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depression rating scales in Parkinson's disease: critique and recommendations.
    Schrag A; Barone P; Brown RG; Leentjens AF; McDonald WM; Starkstein S; Weintraub D; Poewe W; Rascol O; Sampaio C; Stebbins GT; Goetz CG
    Mov Disord; 2007 Jun; 22(8):1077-92. PubMed ID: 17394234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials.
    Khan A; Khan SR; Shankles EB; Polissar NL
    Int Clin Psychopharmacol; 2002 Nov; 17(6):281-5. PubMed ID: 12409681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Hamilton Depression Rating Scale and Montgomery-Åsberg Depression Rating Scale: Baked Straight From a Randomized Study.
    Santi NS; Biswal SB; Naik BN; Sahoo JP; Rath B
    Cureus; 2023 Sep; 15(9):e45098. PubMed ID: 37842359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative sensitivity of the Montgomery-Asberg depression rating scale, the Hamilton depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials: a replication analysis.
    Khan A; Brodhead AE; Kolts RL
    Int Clin Psychopharmacol; 2004 May; 19(3):157-60. PubMed ID: 15107658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hamilton depression rating scale and montgomery-asberg depression rating scale in depressed and bipolar I patients: psychometric properties in a Brazilian sample.
    Carneiro AM; Fernandes F; Moreno RA
    Health Qual Life Outcomes; 2015 Apr; 13():42. PubMed ID: 25889742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The validity of the depression rating scales in discriminating between citalopram and placebo in depression recurrence in the maintenance therapy of elderly unipolar patients with major depression.
    Bent-Hansen J; Lunde M; Klysner R; Andersen M; Tanghøj P; Solstad K; Bech P
    Pharmacopsychiatry; 2003 Nov; 36(6):313-6. PubMed ID: 14663657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation and psychometric properties of the Arabic version of Hamilton Depression Rating Scale 7 items (HAMD-7) among non-clinical and clinical samples of Lebanese adults.
    Obeid S; Azzi V; Hallit S
    PLoS One; 2023; 18(5):e0285665. PubMed ID: 37200339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced attention-dependent auditory processing by electroconvulsive therapy in psychotic depression.
    Nurminen M; Valkonen-Korhonen M; Mervaala E; Pääkkönen A; Partanen J; Viinamäki H; Lehtonen J
    J ECT; 2005 Mar; 21(1):19-24. PubMed ID: 15791173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Hamilton Depression Scale (HAM-D) and the Montgomery-Åsberg Depression Scale (MADRS). A psychometric re-analysis of the European genome-based therapeutic drugs for depression study using Rasch analysis.
    Bech P; Allerup P; Larsen ER; Csillag C; Licht RW
    Psychiatry Res; 2014 Jul; 217(3):226-32. PubMed ID: 24746391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study.
    Hirschfeld RM; Weisler RH; Raines SR; Macfadden W;
    J Clin Psychiatry; 2006 Mar; 67(3):355-62. PubMed ID: 16649820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Systematic Review of the Clinimetric Properties of the 6-Item Version of the Hamilton Depression Rating Scale (HAM-D6).
    Timmerby N; Andersen JH; Søndergaard S; Østergaard SD; Bech P
    Psychother Psychosom; 2017; 86(3):141-149. PubMed ID: 28490031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression.
    Zimmerman M; Posternak MA; Chelminski I
    J Psychiatr Res; 2004; 38(6):577-82. PubMed ID: 15458853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venlafaxine extended-release: a review of its use in the management of major depression.
    Wellington K; Perry CM
    CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Validation of the Spanish versions of the Montgomery-Asberg depression and Hamilton anxiety rating scales].
    Lobo A; Chamorro L; Luque A; Dal-Ré R; Badia X; Baró E;
    Med Clin (Barc); 2002 Apr; 118(13):493-9. PubMed ID: 11975886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.
    Soares CN; Thase ME; Clayton A; Guico-Pabia CJ; Focht K; Jiang Q; Kornstein SG; Ninan PT; Kane CP
    CNS Drugs; 2011 Mar; 25(3):227-38. PubMed ID: 21323394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.